Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 53,075	$ 53,989
Marketable securities	25,529	62,876
Prepaid expenses and other current assets	6,530	5,387
Total current assets	85,134	122,252
Restricted cash	231	231
Other assets, long-term	200	350
Total assets	85,565	122,833
Current liabilities
Accounts payable	6,056	554
Accrued clinical trial expenses	8,459	10,616
Accrued expenses and other current liabilities	10,168	10,072
Debt, short-term	20,404	8,765
Total current liabilities	45,087	30,007
Debt, long-term	5,868	22,396
Total liabilities	50,955	52,403
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2026 and December 31, 2025	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 72,327,320 and 60,575,369 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	7	6
Additional paid-in capital	559,914	516,803
Accumulated deficit	(525,286)	(446,462)
Accumulated other comprehensive (loss) income	(25)	83
Total stockholders’ equity	34,610	70,430
Total liabilities and stockholders’ equity	$ 85,565	$ 122,833

Accrued Clinical Trial Expenses, Current

No definition available.

Name:	abos_AccruedClinicalTrialExpensesCurrent
Namespace Prefix:	abos_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).